argenx SE

ARGX

Equity

ISIN NL0010832176 / Valor 24766616

Euronext - Euronext Brussels (2026-09-29)

EUR 848.40+0.45%

argenx SE
UMushroom community rating:

4.86 3 votes No rating yet

NegativeNeutralPositive

About company

Argenx SE is a biotechnology company that specializes in developing innovative therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary technology platform to create a portfolio of first-in-class product candidates, which are developed in collaboration with academic partners. Argenx's approach focuses on translating breakthroughs in immunology into effective medicines, aiming to address unmet medical needs. The company's flagship product, efgartigimod, is designed to modulate the immune system and is being explored for multiple autoimmune indications. Argenx is headquartered in the Netherlands and operates globally, with a commitment to advancing its pipeline through rigorous research and development efforts.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

38.8%1Y

84.2%3Y

233%5Y

Performance

35.2%1Y

39.0%3Y

39.2%5Y

Volatility

60167 M

Market cap (USD)

59,602

Daily traded volume (Shares)

600 / 594.2

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.86

3 votes

Performance:

4.71

Innovation:

5.00

Society:

4.86

Nature:

3.57

Laura Sofie Tohver

UK, 11 Nov 2025

Emerging technology and nice returns

Viktor Stockel

Switzerland, 30 Oct 2025

Argenx SE is a commercial-stage, global biopharmaceutical company focused on immunology, particularly therapies for severe autoimmune diseases.

Claudia Stadelmann

Switzerland, 05 Mar 2025

Geheimtipp belgisches Biotech mit spannender Pipeline

EQUITIES OF THE SAME SECTOR

IVU Traffic Technologies AG

IVU Traffic Technologies AG Valor: 1099895

Annual Return

-50%0%+50%

Risk level

110

-0.40%EUR 25.20

init innovation in traffic systems SE

init innovation in traffic systems SE Valor: 1265285

Annual Return

-50%0%+50%

Risk level

110

-1.30%EUR 45.50

Fabasoft AG

Fabasoft AG Valor: 814216

Annual Return

-50%0%+50%

Risk level

110

-1.24%EUR 15.90

All for One Group SE

All for One Group SE Valor: 192106

Annual Return

-50%0%+50%

Risk level

110

0.00%EUR 68.60

SNP Schneider-Neureither & Partner SE

SNP Schneider-Neureither & Partner SE Valor: 1060617

Annual Return

-50%0%+50%

Risk level

110

3.33%EUR 87.00

BRAIN Biotech AG

BRAIN Biotech AG Valor: 30933824

Annual Return

-50%0%+50%

Risk level

110

2.15%EUR 2.85

Dr.Hoenle AG

Dr.Hoenle AG Valor: 1174437

Annual Return

-50%0%+50%

Risk level

110

-0.80%EUR 7.48

ecotel communication ag

ecotel communication ag Valor: 2489718

Annual Return

-50%0%+50%

Risk level

110

-0.74%EUR 6.70

Orbis SE

Orbis SE Valor: 1124238

Annual Return

-50%0%+50%

Risk level

110

0.00%EUR 4.70

MeVis Medical Solutions AG

MeVis Medical Solutions AG Valor: 3537049

Annual Return

-50%0%+50%

Risk level

110

0.00%EUR 22.60

Logos provided by Clearbit

argenx SE

ARGX

ISIN NL0010832176 / Valor 24766616

argenx SE UMushroom community rating:

Laura Sofie Tohver

Viktor Stockel

Claudia Stadelmann

argenx SE
UMushroom community rating: